Fichtner, M.L.* ; Rübsamen, H.* ; Smolle, M.* ; Schaller, J.* ; Feederle, R. ; Bültmann, A.* ; Kümpfel, T.* ; Schneider, P.* ; Thaler, F.S.* ; Meinl, E.*
Features of isoforms of human soluble TACI.
J. Immunol. 211, 199-208 (2023)
The BAFF/APRIL-system with the two cytokines BAFF and APRIL and their three receptors, transmembrane activator and CAML interactor (TACI), BAFF receptor, and B-cell maturation Ag, is important for B cell maintenance. The BAFF/APRIL system is a therapeutic target in B cell-derived malignancies and autoimmune diseases. However, unexpected outcomes of clinical trials with atacicept (TACI-Fc) underline our incomplete understanding of this system. Shedding of the three receptors is one important regulatory element. In humans, TACI exists in two isoforms generated through alternative splicing in their extracellular portion: TACI-long (l) has two cysteine-rich domains, whereas TACI-short (s) lacks the first low-affinity one. In this study, we discriminated soluble (s) forms of TACI-l and TACI-s with newly generated mAbs and found that both were spontaneously released from activated human B cells, with a predominance of sTACI-l. Furthermore, sTACI-l was also the dominant isoform in human serum. Vaccination with the mRNA vaccine from BioNTech does not significantly affect the serum levels of sTACI-l. Both TACI-s and TACI-l were shed by a disintegrin and metalloproteinase domain-containing protein 10. TACI-l and TACI-s formed homo- and hetero-oligomers in soluble and membrane-bound forms. Both sTACI-l and sTACI-s acted as decoy receptors for BAFF, but only sTACI-l also efficiently inhibited APRIL. Dimerization of sTACI-l enhanced its decoy functions only slightly. Together, we extend our knowledge of the complexity of the BAFF/APRIL system by identifying and characterizing the two soluble isoforms of TACI.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Typ der Hochschulschrift
Herausgeber
Schlagwörter
Common Variable Immunodeficiency; Crystal-structure; Receptor; April; Baff; Bcma; Immunoregulator; Therapy; Antigen; System
Keywords plus
Sprache
englisch
Veröffentlichungsjahr
2023
Prepublished im Jahr
0
HGF-Berichtsjahr
2023
ISSN (print) / ISBN
0022-1767
e-ISSN
1550-6606
ISBN
Bandtitel
Konferenztitel
Konferzenzdatum
Konferenzort
Konferenzband
Quellenangaben
Band: 211,
Heft: 2,
Seiten: 199-208
Artikelnummer: ,
Supplement: ,
Reihe
Verlag
American Association of Immunologists
Verlagsort
9650 Rockville Pike, Bethesda, Md 20814 Usa
Tag d. mündl. Prüfung
0000-00-00
Betreuer
Gutachter
Prüfer
Topic
Hochschule
Hochschulort
Fakultät
Veröffentlichungsdatum
0000-00-00
Anmeldedatum
0000-00-00
Anmelder/Inhaber
weitere Inhaber
Anmeldeland
Priorität
Begutachtungsstatus
Peer reviewed
Institut(e)
CF Monoclonal Antibodies (CF-MAB)
POF Topic(s)
30201 - Metabolic Health
Forschungsfeld(er)
Helmholtz Diabetes Center
PSP-Element(e)
G-502210-001
Förderungen
Deutsche Forschungsgemeinschaft research fellowship
Swiss National Science Foundation
Munich Cluster for Systems Neurology (SyNergy)
Else-Kroner Fresenius Stiftung
Gemeinnutzige Hertie Stiftung
Novartis Pharma
Merck
Deutsche Forschungsgemeinschaft
Copyright
Erfassungsdatum
2023-10-06